Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Genitourinary 1

Conditions

Glioblastoma 3Urinary Bladder Neoplasms 1Rhabdoid Tumor 1Recurrence 1Prostatic Neoplasms 1Multiple Myeloma 1Lymphoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × gallium maltolate × Clear all
NCT00050687 2011-01-28

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Titan Pharmaceuticals

Phase 1/2 Terminated
GenitourinaryLymphoidPlasma cell

Urinary Bladder Neoplasms, Lymphoma, Multiple Myeloma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡